Recurrent neurosurgical site infection by extensively drug-resistant P. aeruginosa treated with cefiderocol: a case report and literature review.

Abstract

INTRODUCTION:

Cefiderocol is a new siderophore cephalosporin designed to be active against extensively resistant Gram-negative bacteria; however, clinical studies are limited to complicated urinary tract infections, pneumonia, and intra-abdominal infections. To date, no data are available on neurosurgical site infections.

CASE PRESENTATION:

We present a case of a patient successfully cured with Cefiderocol for a neurosurgical site infection due to extensively resistant P. aeruginosa, who had failed a previous treatment based on combined antimicrobial therapy and right parietal bone excision.

CONCLUSIONS:

Cefiderocol is a promising antibiotic for complicated infections due to multidrug resistant gram-negative bacteria.

• Authors: Davide Fiore Bavaro, Federica Romanelli, Stefania Stolfa, Alessandra Belati, Lucia Diella, Luigi Ronga, Cecilia Fico, Laura Monno, Adriana Mosca, Annalisa Saracino
• Journal: Infectious diseases (London, England) (Infect Dis (Lond)) Vol. 53 Issue 3 Pg. 206-211 (Mar 2021) ISSN: 2374-4243 [Electronic] England
• PMID: 33295821 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Cephalosporins
• Pharmaceutical Preparations
• cefiderocol

Topics

• Anti-Bacterial Agents (therapeutic use)
• Cephalosporins (therapeutic use)
• Gram-Negative Bacteria
• Humans
• Pharmaceutical Preparations
• Pseudomonas aeruginosa